Hans Orlent
Overview
Explore the profile of Hans Orlent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lejeune A, Starkel P, Louvet A, Hittelet A, Bazille C, Bastens B, et al.
Transl Gastroenterol Hepatol
. 2025 Feb;
10:3.
PMID: 39944578
Background: Keratin 7 positive (K7) cells are considered to be activated in case of impaired hepatocyte replication. Their exact role and their interaction with hepatocytes and macrophages also implicated in...
2.
Furquim dAlmeida A, Ho E, Govaerts L, Michielsen P, Serste T, Bourgeois S, et al.
J Viral Hepat
. 2025 Jan;
32(2):1-15.
PMID: 39846497
Hepatitis B virus (HBV)-hepatitis delta virus (HDV) coinfection is the most severe form of chronic viral hepatitis, but the factors that determine disease progression and severity are incompletely characterised. This...
3.
Nault J, Sritharan N, Verset G, Borbath I, Lequoy M, Allaire M, et al.
JHEP Rep
. 2025 Jan;
6(11):101192.
PMID: 39741695
Background & Aims: We aimed to explore patient expectations regarding their treatments and prognosis in comparison to physicians' assessments in patients with advanced hepatocellular carcinoma (HCC) receiving systemic treatments. Methods:...
4.
Grossar L, Raevens S, Van Steenkiste C, Colle I, De Vloo C, Orlent H, et al.
JHEP Rep
. 2024 Sep;
6(9):101149.
PMID: 39247177
Background & Aims: The goal of treatment in autoimmune hepatitis (AIH) is induction of remission to prevent the development of liver fibrosis, cirrhosis, and its related complications. Various definitions of...
5.
Billiet A, Temmerman F, Coudyzer W, Van den Ende N, Colle I, Francque S, et al.
United European Gastroenterol J
. 2023 Jun;
11(7):633-641.
PMID: 37278135
Background And Aims: Polycystic liver disease (PLD) can lead to extensive hepatomegaly. Symptom relief is the primary goal of the treatment. The role of the recently developed disease-specific questionnaires for...
6.
Busschots D, Kremer C, Bielen R, Koc O, Heyens L, Brixko C, et al.
BMC Infect Dis
. 2021 Jul;
21(1):708.
PMID: 34315415
Background: Prevalence data on viral hepatitis B (HBV), hepatitis C (HCV), and HIV infection in prison are often scarce or outdated. There is currently no systematic screening for these blood-borne...
7.
Vliebergh J, Deprez P, De Looze D, Ferrante M, Orlent H, Macken E, et al.
Endoscopy
. 2018 Oct;
51(4):317-325.
PMID: 30360011
Background: Radiofrequency ablation (RFA), combined with endoscopic resection, can be used as a primary treatment for low grade dysplasia, high grade dysplasia, and early esophageal adenocarcinoma (EAC) in Barrett's esophagus...
8.
Marot A, Belaid A, Orlent H, Serste T, Michielsen P, Colle I, et al.
Clin Res Hepatol Gastroenterol
. 2017 Sep;
41(6):656-663.
PMID: 28867077
Aims: To assess the main characteristics of patients with HBV and HCV dual infection, to compare these with those of patients infected with either HBV or HCV and, among patients...
9.
Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arasteh K, et al.
BMC Gastroenterol
. 2017 Feb;
17(1):26.
PMID: 28187751
Background: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the...
10.
Degre D, Serste T, Lasser L, Delwaide J, Starkel P, Laleman W, et al.
PLoS One
. 2017 Jan;
12(1):e0170933.
PMID: 28125694
Introduction: Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in...